|Table of Contents|

Comparison of clinical efficacy between FOLFIRI regimen used alone and combined with bevacizumab in first-line treatment of patients with rectal cancer in IV stage

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 02
Page:
263-266
Research Field:
Publishing date:

Info

Title:
Comparison of clinical efficacy between FOLFIRI regimen used alone and combined with bevacizumab in first-line treatment of patients with rectal cancer in IV stage
Author(s):
Shi Xiuhuan
The Health Center，the Affiliated Hospital of Inner Mongolia Medical University,Inner Mongolia Hohhot 010059,China.
Keywords:
FOLFIRI regimen; bevacizumab; rectal cancer; clinical effects; safety
PACS:
R735.37
DOI:
10.3969/j.issn.1672-4992.2017.02.027
Abstract:
Objective：To investigate clinical effects and safety of FOLFIRI regimen used alone and combined with bevacizumab in first-line treatment of patients with rectal cancer in IV stage.Methods：All 90 patients with rectal cancer in IV stage were chosen in the period from April 2012 to April 2013 in our hospital and randomly divided into two groups including A group (45 patients) with FOLFIRI regimen used alone and B group (45 patients) with FOLFIRI regimen combined with bevacizumab.Results：The clinical efficacy of short-term of group B was significantly better than group A（P＜0.05）.The survival rate of B group was significantly higher than A group（P＜0.05）.The KPS score of B group after treatment was significant better than A group and before treatment（P＜0.05）.There was no significant difference in drug side effects between two groups （P＞0.05）.Conclusion：Compared with FOLFIRI regimen used alone,FOLFIRI regimen combined with bevacizumab in first-line treatment of patients with rectal cancer in IV stage can efficiently delay the progress of disease,improve the survival rate and quality of life,without serious side effects.

References:

［1］Yang DY,Li Y,Liu JH.Study of capecitabine maintence therapy effectiveness on metastatic colorectal cancer patients with disease optimally controlled after the chemotherapy［J］.J Practical Med,2013,29(8):1299-1300.［杨冬阳,黎莹,刘建化.转移性结直肠癌化疗控制后卡培他滨维持治疗分析［J］.实用医学杂志,2013,29(8):1299-1300.］
[2]Gao W,Liu LX,Zhu WY.Evaluation of bevacizumab combined with chemotherapy for the first-line treatment on patients with metastatic colorectal cancer ［J］.Chin J Surg Oncol,2014,6(6):345-349.［高雯,刘凌翔,朱蔚友.贝伐珠单抗联合一线化疗晚期转移性结直肠癌的临床观察［J］.中国肿瘤外科杂志,2014,6(6):345-349.］
[3]Fitzgerald TL,Lea CS,Brinkley J,et al.Colorectal cancer outcome inequalities:Association between population density,race,and socioeconomic status ［J］.Rural Remote Health,2014,14(3):2668.
[4]Giardiello FM,Allen JI,Axilbund JE,et al.Guidelines on genetic evaluation and management of lynch syndrome:A consensus statement by the US multi-society task force on colorectal cancer［J］.Gastroenterology,2014,147(5):502-526.
[5]Zhu LJ,Li S,Feng JF,et al.Phase II clinical study of cetuximab combined with FOLFIRI biweekly regimen in the treatment of patients with advanced stage of colorectal cancer for wild type K-Ras gene ［J］.J Clin Oncol,2013,18(1):39-44.［朱梁军,李晟,冯继锋,等.西妥昔单抗联合FOLFIRI双周方案在野生型 K-Ｒas 基因晚期结直肠癌患者中的Ⅱ期临床观察［J］.临床肿瘤学杂志,2013,18(1):39-44.］
[6]Lee EK,Revil C,Ngoh CA,et al.Clinical and cost effectiveness of bevacizumab + FOLFIＲI combination versus FOLFIＲI alone as first-line treatment of metastatic colorectal cancer in South Korea ［J］.Clin Ther,2012,34(6):1408-1419.
[7]Bagnasco L,Piras D,Parodi S,et al.Role of angiogenesis inhibitors in colorectal cancer:Sensitive and insensitive tumors ［J］.Curr Cancer Drug Targets,2012,12(4):303-315.
[8]Koukourakis GV.Has bevacizumab(Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas systematic review answering this question［J］.Recent Pat Inflamm Allergy Drug Discov,2012,6(1):70-77.
[9]Xue Z,Cao J,Zhou J.Clinical observation of irinotecan combiend with capecitabine on advanced colorectal cancer with progression after oxaliplatin chemotherapy ［J］.Chin J Clin Oncol Rehabilitation,2012,19(6):493-494.［薛忠,曹杰,周俭.伊立替康联合卡培他滨治疗奥沙利铂化疗后进展的晚期结直肠癌的临床观察［J］.中国肿瘤临床与康复,2012,19(6):493-494.］
[10]Zhang NG,Wang YS,Zhang CY.Efficacy and safety of bevacizumab plus chemotherapy in treatment of patients with metastatic colorectal cancer ［J］.Cancer Research and Clinic,2014,26(11):741-743,748.［张宁刚,王育生,张成琰.贝伐珠单抗联合化疗治疗转移性结直肠癌的近期效果及安全性［J］.肿瘤研究与临床,2014,26(11):741-743,748.］
[11]Yang Y,Cai QC,Zou DW,et al.Research progress of molecular targeted therapy for advanced colorectal cancer ［J］.Chin J Tumor Biol Therap,2013,20(2):247-250.［杨阳,蔡全才,邹多武,等.晚期结直肠癌分子靶向治疗的研究进展［J］.中国肿瘤生物治疗杂志,2013,20(2):247-250.］
[12]Li R,Zhao BQ,Zhang YH.Analysis of the adverse effects of bevacizumab in the treatment of malignant tumors ［J］.Chin J New Drug,2013,22(17):2097-2102.［李然,赵冰清,张艳华.贝伐珠单抗治疗恶性肿瘤的不良反应分析［J］.中国新药杂志,2013,22(17):2097-2102.］
[13]Chai Yanlan,Xiao Juxiang,Suo Aili,et al.Clinical observation of bevacizumab combined with chemotherapy in treatment of advanced colorectal cancer ［J］.Modern Oncology,2013,21(9):2040-2043.［柴延兰,肖菊香,锁爱莉,等.贝伐珠单抗联合化疗治疗晚期结直肠癌的临床观察［J］.现代肿瘤医学,2013,21(9):2040-2043.］
[14]Wang W,Xiao J.The therapeutic effect observation of bevacizumab in combination with biweekly regimen in the treatment of 45 cases patients with metastatic colorectal cancer ［J］.Cancer,2013,33(10):914-918.［王巍,肖健.贝伐珠单抗联合双周方案治疗45例转移性结直肠癌的临床疗效观察［J］.肿瘤,2013,33(10):914-918.］

Memo

Memo:
-
Last Update: 2016-12-01